Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy

What Was Tested

The paper reports a study of Liraglutide in the context of diabetic retinopathy and glaucoma, published as a randomized controlled trial.

The primary endpoint was a change in peripapillary RNFL thickness between treatments, assessed by optical coherence tomography.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Methods: Secondary analyses were performed on a prospective, double-blinded, randomized, placebo-controlled trial on adults with type 1 diabetes, distal symmetric polyneuropathy (DSPN), and confirmed diabetic retinopathy, who were randomized 1:1 to either 26 weeks placebo or liraglutide treatment.

Results: Thirty-seven participants were included in the secondary analysis.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Liraglutide.

Some participants received a placebo instead of Liraglutide, giving a reference point.

What Was Measured

The primary endpoint was a change in peripapillary RNFL thickness between treatments, assessed by optical coherence tomography.

Topics PubMed links to this paper include Diabetes Mellitus, Type 1, Diabetic Retinopathy, Liraglutide, Nerve Fibers, Retina and Tomography, Optical Coherence.

The authors tagged it with the keywords GLP-1 agonist, nerve fiber layer and optical coherence tomography.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in people with diabetic retinopathy and glaucoma.

The publication is from 2022 (Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics), a journal based in United States.

More context: the Liraglutide compound page, Diabetic retinopathy and glaucoma research.